Intra-Cellular Therapies Inc
NASDAQ:ITCI
Intra-Cellular Therapies Inc
NASDAQ:ITCI
Price:
131.87
USD
-0.04%
Market Closed
Market Cap:
$14B
Balance Sheet
Balance Sheet Decomposition
Intra-Cellular Therapies Inc
Intra-Cellular Therapies Inc
Balance Sheet Decomposition is not available for
Intra-Cellular Therapies Inc
Intra-Cellular Therapies Inc
Balance Sheet
Intra-Cellular Therapies Inc
Intra-Cellular Therapies Inc
Currency: USD
| Dec-2011 | Dec-2012 | Dec-2013 | Dec-2014 | Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||||||
| Cash & Cash Equivalents |
14
|
16
|
35
|
61
|
47
|
49
|
38
|
55
|
108
|
60
|
92
|
149
|
148
|
307
|
|
| Cash Equivalents |
14
|
16
|
35
|
61
|
47
|
49
|
38
|
55
|
108
|
60
|
92
|
149
|
148
|
307
|
|
| Short-Term Investments |
9
|
4
|
2
|
68
|
428
|
336
|
427
|
293
|
116
|
597
|
320
|
443
|
350
|
694
|
|
| Total Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
11
|
20
|
75
|
114
|
167
|
|
| Accounts Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
11
|
20
|
75
|
114
|
167
|
|
| Other Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Inventory |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
7
|
8
|
24
|
12
|
26
|
|
| Other Current Assets |
0
|
0
|
1
|
1
|
8
|
4
|
5
|
8
|
6
|
16
|
27
|
47
|
44
|
114
|
|
| Total Current Assets |
23
|
20
|
38
|
131
|
483
|
388
|
469
|
355
|
230
|
691
|
467
|
738
|
668
|
1 307
|
|
| PP&E Net |
0
|
0
|
0
|
0
|
1
|
1
|
1
|
1
|
21
|
26
|
23
|
17
|
15
|
15
|
|
| PP&E Gross |
0
|
0
|
0
|
0
|
1
|
1
|
1
|
1
|
21
|
26
|
23
|
17
|
0
|
0
|
|
| Accumulated Depreciation |
3
|
3
|
3
|
2
|
2
|
3
|
3
|
3
|
4
|
4
|
5
|
5
|
0
|
0
|
|
| Other Long-Term Assets |
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
0
|
0
|
0
|
0
|
46
|
45
|
|
| Total Assets |
24
N/A
|
20
-16%
|
38
+94%
|
131
+241%
|
484
+269%
|
389
-20%
|
472
+21%
|
357
-24%
|
251
-30%
|
717
+186%
|
490
-32%
|
755
+54%
|
728
-4%
|
1 367
+88%
|
|
| Liabilities | |||||||||||||||
| Accounts Payable |
1
|
0
|
3
|
2
|
2
|
4
|
6
|
14
|
7
|
6
|
9
|
10
|
11
|
26
|
|
| Accrued Liabilities |
2
|
1
|
3
|
9
|
5
|
7
|
8
|
22
|
29
|
31
|
45
|
73
|
112
|
180
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Liabilities |
2
|
2
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Current Liabilities |
4
|
3
|
7
|
11
|
6
|
11
|
14
|
36
|
36
|
37
|
53
|
83
|
124
|
206
|
|
| Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Liabilities |
2
|
0
|
0
|
0
|
2
|
3
|
3
|
3
|
20
|
24
|
19
|
16
|
13
|
13
|
|
| Total Liabilities |
6
N/A
|
3
-51%
|
7
+143%
|
11
+56%
|
8
-25%
|
13
+70%
|
17
+27%
|
40
+132%
|
56
+42%
|
61
+8%
|
72
+19%
|
99
+37%
|
137
+39%
|
218
+60%
|
|
| Equity | |||||||||||||||
| Common Stock |
29
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Retained Earnings |
14
|
31
|
58
|
88
|
193
|
310
|
407
|
562
|
710
|
937
|
1 221
|
1 478
|
1 617
|
1 692
|
|
| Additional Paid In Capital |
3
|
48
|
89
|
209
|
670
|
685
|
863
|
881
|
905
|
1 594
|
1 640
|
2 138
|
2 208
|
2 840
|
|
| Other Equity |
0
|
0
|
0
|
0
|
1
|
0
|
1
|
1
|
0
|
1
|
0
|
4
|
0
|
0
|
|
| Total Equity |
18
N/A
|
17
-5%
|
32
+86%
|
121
+282%
|
476
+295%
|
376
-21%
|
454
+21%
|
318
-30%
|
195
-39%
|
657
+237%
|
418
-36%
|
656
+57%
|
591
-10%
|
1 148
+94%
|
|
| Total Liabilities & Equity |
24
N/A
|
20
-16%
|
38
+94%
|
131
+241%
|
484
+269%
|
389
-20%
|
472
+21%
|
357
-24%
|
251
-30%
|
717
+186%
|
490
-32%
|
755
+54%
|
728
-4%
|
1 367
+88%
|
|
| Shares Outstanding | |||||||||||||||
| Common Shares Outstanding |
11
|
15
|
22
|
30
|
43
|
43
|
55
|
55
|
56
|
81
|
82
|
95
|
96
|
106
|
|
Switch to:
Switch to:
See Also
Discover More
